News
BDTX
2.045
-2.15%
-0.045
Weekly Report: what happened at BDTX last week (0803-0807)?
Weekly Report · 2d ago
Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2
TipRanks · 6d ago
Black Diamond Therapeutics setup ‘attractive,’ says Jefferies
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)
TipRanks · 6d ago
Black Diamond Therapeutics GAAP EPS of -$0.17 beats by $0.03
Seeking Alpha · 6d ago
Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate
Benzinga · 6d ago
Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c)
TipRanks · 6d ago
Press Release: Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 6d ago
*Black Diamond Theraptcs 2Q Loss/Shr 17c >BDTX
Dow Jones · 6d ago
Press Release: Black Diamond Therapeutics Reports -2-
Dow Jones · 6d ago
Black Diamond: Q2 Earnings Snapshot
Barchart · 08/05 15:55
Weekly Report: what happened at BDTX last week (0727-0731)?
Weekly Report · 08/03 09:27
Weekly Report: what happened at BDTX last week (0720-0724)?
Weekly Report · 07/27 09:29
Weekly Report: what happened at BDTX last week (0713-0717)?
Weekly Report · 07/20 09:27
Weekly Report: what happened at BDTX last week (0706-0710)?
Weekly Report · 07/13 09:28
Weekly Report: what happened at BDTX last week (0629-0703)?
Weekly Report · 07/06 09:29
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Seeking Alpha · 07/06 05:51
Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth
Simply Wall St · 07/01 10:43
Black Diamond Shareholders Approve Directors and Annual Say-on-Pay
TipRanks · 06/29 20:52
Weekly Report: what happened at BDTX last week (0622-0626)?
Weekly Report · 06/29 09:27
More
Webull provides a variety of real-time BDTX stock news. You can receive the latest news about Black Diamond Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.